Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.

Clinical hematology international·2026
Same author

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B-Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community-Based Centers and for Outpatient Step-Up Dosing.

EJHaem·2026
Same author

Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.

HemaSphere·2026
Same author

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Leukemia·2025
Same author

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Nature medicine·2024

Related Experiment Video

Updated: Jul 14, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

[Angioimmunoblastic T-cell lymphoma].

Florence Lachenal1

  • 1Service de médecine interne, Centre hospitalier Lyon Sud, Pierre-Bénite. flo.lachenal@free.fr

Presse Medicale (Paris, France : 1983)
|June 26, 2007
PubMed
Summary

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive non-Hodgkin lymphoma primarily affecting older adults. Diagnosis requires lymph node biopsy and genetic analysis, with a 5-year survival rate of 30%.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of peripheral T-cell lymphoma.
  • It predominantly affects elderly individuals, presenting with systemic symptoms and lymphadenopathy.
  • Key laboratory findings include polyclonal hypergammaglobulinemia, elevated LDH, and anemia.

Purpose:

  • To summarize the clinical presentation, diagnostic criteria, and treatment approaches for Angioimmunoblastic T-cell lymphoma.
  • To highlight the common complications, including autoimmune phenomena and infections.
  • To provide an overview of the prognosis and survival rates associated with AITL.

Summary:

  • AITL typically manifests with generalized lymphadenopathy, hepatosplenomegaly, rash, and systemic symptoms.

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Related Experiment Videos

Last Updated: Jul 14, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

  • Diagnosis is confirmed by lymph node biopsy showing a monoclonal T-cell population, alongside characteristic laboratory abnormalities and frequent autoimmune features.
  • Treatment strategies vary by age and disease status, including chemotherapy, autologous stem cell transplantation, and immunosuppressive drugs.

    • Impact:

    • This information aids clinicians in the timely diagnosis and management of AITL.
    • Understanding AITL's complexities can improve patient outcomes and guide further research.
    • Highlights the need for multidisciplinary care, addressing both the malignancy and associated immune dysregulation.